home · filing · 0000950170-23-062492
8-K filed November 13, 2023, 6:59 PM ET
ticker INGN
CIK 0001294133
leadership
confidence high
sentiment neutral
materiality 0.75
Inogen names Kevin Smith President and CEO; new compensation includes $1.7M sign-on bonus
Inogen Inc
Kevin Smith appointed President and CEO effective Nov 10, 2023, succeeding Nabil Shabshab who departed same day.
Smith brings over 20 years med-device leadership, most recently CEO of Sirtex Medical.
Compensation: $700K salary, 100% target bonus, $1.7M sign-on bonus (two installments), 170K equity (RSUs + PSUs).
Full-year 2023 financial guidance reaffirmed; company will skip Stifel and Piper Sandler conferences.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Appointed
Kevin Smith
Class III director
Effective 2023-11-10
Filed November 13, 2023, 6:59 PM ET
appointed Mr. Smith to serve as a Class III director of the Company, effective November 10, 2023.
Effective 2023-11-10
Filed November 13, 2023, 6:59 PM ET
appointed Kevin Smith to serve as President and Chief Executive Officer ("CEO") of the Company, effective November 10, 2023.
Effective 2023-11-10
Successor Kevin Smith
Filed November 13, 2023, 6:59 PM ET
Mr. Shabshab's role as an officer and employee of the Company ended effective November 10, 2023.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kevin Smith was appointed as Class III director at Inogen Inc.
Action appointed
Role Class III director
Exact text from the filing
appointed Mr. Smith to serve as a Class III director of the Company, effective November 10, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kevin Smith was appointed as President and Chief Executive Officer at Inogen Inc.
Action appointed
Role President and Chief Executive Officer
Exact text from the filing
appointed Kevin Smith to serve as President and Chief Executive Officer ("CEO") of the Company, effective November 10, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nabil Shabshab departed as President and Chief Executive Officer at Inogen Inc.
Action ended
Role President and Chief Executive Officer
Exact text from the filing
Mr. Shabshab's role as an officer and employee of the Company ended effective November 10, 2023.
View on SEC.gov
Source: SEC EDGAR
accession 0000950170-23-062492
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.